AGÕæÈ˹ٷ½

STOCK TITAN

[S-8] Rigel Pharmaceuticals Inc. (New) Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

On 6 Aug 2025, Rigel Pharmaceuticals (RIGL) filed a routine Form S-8 to register 825,000 additional common shares for employee equity compensation: 125,000 shares under the Inducement Plan and 700,000 shares under the 2018 Equity Incentive Plan. The filing incorporates prior S-8s by reference and includes the usual legal opinions, consents and power-of-attorney exhibits; it contains no new earnings, balance-sheet data or corporate actions beyond the share registration. The statement ensures Rigel has sufficient shares available for future option and restricted-stock grants, supporting talent recruitment and retention. While the registration itself does not raise capital, any subsequent issuance of the shares will incrementally dilute existing shareholders.

Il 6 agosto 2025, Rigel Pharmaceuticals (RIGL) ha presentato un modulo S-8 ordinario per registrare ulteriori 825.000 azioni ordinarie destinate alla compensazione azionaria dei dipendenti: 125.000 azioni nell'ambito del Piano di Induzione e 700.000 azioni nell'ambito del Piano di Incentivi Azionari 2018. La presentazione incorpora per riferimento i precedenti moduli S-8 e include le consuete opinioni legali, consensi e procure; non contiene nuovi dati relativi a utili, bilanci o azioni societarie oltre alla registrazione delle azioni. La dichiarazione garantisce che Rigel disponga di azioni sufficienti per future concessioni di opzioni e azioni vincolate, supportando il reclutamento e la fidelizzazione del personale. Sebbene la registrazione stessa non comporti raccolta di capitale, qualsiasi successiva emissione di azioni comporterà una diluizione incrementale degli azionisti esistenti.

El 6 de agosto de 2025, Rigel Pharmaceuticals (RIGL) presentó un formulario S-8 rutinario para registrar 825,000 acciones comunes adicionales destinadas a la compensación accionaria de empleados: 125,000 acciones bajo el Plan de Inducción y 700,000 acciones bajo el Plan de Incentivos de Acciones 2018. La presentación incorpora por referencia formularios S-8 anteriores e incluye los habituales dictámenes legales, consentimientos y poderes notariales; no contiene datos nuevos sobre ganancias, balances o acciones corporativas más allá del registro de acciones. La declaración asegura que Rigel cuenta con suficientes acciones disponibles para futuras concesiones de opciones y acciones restringidas, apoyando la contratación y retención de talento. Aunque la registración en sí no genera capital, cualquier emisión posterior de acciones diluirá progresivamente a los accionistas existentes.

2025ë…� 8ì›� 6ì�, Rigel Pharmaceuticals(RIGL)ëŠ� ì§ì› ì£¼ì‹ ë³´ìƒì� 위해 추가ë¡� 825,000ì£¼ì˜ ë³´í†µì£¼ë¥¼ 등ë¡í•˜ëŠ” 정기 Form S-8ì� 제출했습니다: ìœ ë„ ê³„íš í•˜ì— 125,000ì£�, 2018ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ ê³„íš í•˜ì— 700,000주입니다. ì´ë²ˆ ì œì¶œì€ ì´ì „ì� S-8 문서ë¥� 참조ë¡� í¬í•¨í•˜ë©°, ì¼ë°˜ì ì¸ 법률 ì˜ê²¬ì„�, ë™ì˜ì„� ë°� 위임ìž� ë¶€ì†ì„œë¥˜ë¥¼ í¬í•¨í•˜ê³  있습니다. 새로ìš� 수ìµ, 재무ìƒíƒœí‘� ë°ì´í„°ë‚˜ ì£¼ì‹ ë“±ë¡ ì™¸ì˜ ê¸°ì—… 활ë™ì€ í¬í•¨ë˜ì–´ 있지 않습니다. ì� ì„±ëª…ì€ Rigelì� 향후 ì£¼ì‹ ì˜µì…˜ ë°� 제한 ì£¼ì‹ ë¶€ì—¬ë¥¼ 위한 ì¶©ë¶„í•� 주ì‹ì� 보유하고 있ìŒì� 보장하며, ì¸ìž¬ 유치 ë°� 유지ì—� 기여합니ë‹�. ë“±ë¡ ìžì²´ëŠ� ìžë³¸ì� 조달하지 않지ë§�, ì´í›„ ì£¼ì‹ ë°œí–‰ì€ ê¸°ì¡´ ì£¼ì£¼ë“¤ì˜ ì§€ë¶� í¬ì„ì� ì ì§„ì ìœ¼ë¡� 초래í•� 것입니다.

Le 6 août 2025, Rigel Pharmaceuticals (RIGL) a déposé un formulaire S-8 de routine pour enregistrer 825 000 actions ordinaires supplémentaires destinées à la rémunération en actions des employés : 125 000 actions dans le cadre du Plan d'Induction et 700 000 actions dans le cadre du Plan d'Incitation en Actions 2018. Le dépôt intègre par référence les précédents formulaires S-8 et inclut les avis juridiques habituels, consentements et procurations annexes ; il ne contient aucune nouvelle donnée sur les résultats, le bilan ou des actions corporatives au-delà de l'enregistrement des actions. Cette déclaration garantit que Rigel dispose d'actions suffisantes pour les futures attributions d'options et d'actions restreintes, soutenant ainsi le recrutement et la fidélisation des talents. Bien que l'enregistrement lui-même ne génère pas de capital, toute émission ultérieure des actions diluera progressivement les actionnaires existants.

Am 6. August 2025 reichte Rigel Pharmaceuticals (RIGL) ein routinemäßiges Formular S-8 ein, um 825.000 zusätzliche Stammaktien für die Mitarbeiterbeteiligung zu registrieren: 125.000 Aktien im Rahmen des Inducement-Plans und 700.000 Aktien im Rahmen des Equity Incentive Plans 2018. Die Einreichung bezieht sich auf frühere S-8-Formulare und enthält die üblichen Rechtsgutachten, Zustimmungen und Vollmachtsanhänge; sie enthält keine neuen Gewinn-, Bilanzdaten oder Unternehmensmaßnahmen über die Aktienregistrierung hinaus. Die Erklärung stellt sicher, dass Rigel ausreichend Aktien für zukünftige Optionen und Restricted-Stock-Zuteilungen zur Verfügung hat, um die Rekrutierung und Bindung von Talenten zu unterstützen. Obwohl die Registrierung selbst kein Kapital einbringt, wird jede spätere Ausgabe der Aktien die bestehenden Aktionäre schrittweise verwässern.

Positive
  • Ensures share availability for future employee and new-hire equity awards, supporting talent retention and recruitment.
  • Demonstrates regulatory compliance by properly incorporating prior S-8 filings and related corporate documents.
Negative
  • Incremental shareholder dilution will occur as the 825,000 shares are issued under the plans.
  • Continued reliance on equity compensation may pressure share count growth over time.

Insights

TL;DR: Administrative S-8 adds 825k shares for compensation; neutral impact, minor future dilution.

The filing merely expands Rigel’s equity pool�125k inducement shares and 700k incentive shares—keeping its compensation plans funded. No capital is raised and no immediate P&L effects occur. Future dilution is modest and typical for biotech peers. Given the company’s historical reliance on equity awards, investors should monitor total share count trends, but this single increase is not material to valuation.

TL;DR: Standard housekeeping; reflects ongoing use of equity-based pay.

Form S-8 follows SEC General Instruction E, piggybacking on earlier registrations. Inclusion of updated certificates and bylaws shows good filing hygiene. Use of an inducement plan aligns with NASDAQ rules for new hires, suggesting continued hiring activity. Governance risk is limited, though persistent share grants can erode voting power if not balanced with performance metrics.

Il 6 agosto 2025, Rigel Pharmaceuticals (RIGL) ha presentato un modulo S-8 ordinario per registrare ulteriori 825.000 azioni ordinarie destinate alla compensazione azionaria dei dipendenti: 125.000 azioni nell'ambito del Piano di Induzione e 700.000 azioni nell'ambito del Piano di Incentivi Azionari 2018. La presentazione incorpora per riferimento i precedenti moduli S-8 e include le consuete opinioni legali, consensi e procure; non contiene nuovi dati relativi a utili, bilanci o azioni societarie oltre alla registrazione delle azioni. La dichiarazione garantisce che Rigel disponga di azioni sufficienti per future concessioni di opzioni e azioni vincolate, supportando il reclutamento e la fidelizzazione del personale. Sebbene la registrazione stessa non comporti raccolta di capitale, qualsiasi successiva emissione di azioni comporterà una diluizione incrementale degli azionisti esistenti.

El 6 de agosto de 2025, Rigel Pharmaceuticals (RIGL) presentó un formulario S-8 rutinario para registrar 825,000 acciones comunes adicionales destinadas a la compensación accionaria de empleados: 125,000 acciones bajo el Plan de Inducción y 700,000 acciones bajo el Plan de Incentivos de Acciones 2018. La presentación incorpora por referencia formularios S-8 anteriores e incluye los habituales dictámenes legales, consentimientos y poderes notariales; no contiene datos nuevos sobre ganancias, balances o acciones corporativas más allá del registro de acciones. La declaración asegura que Rigel cuenta con suficientes acciones disponibles para futuras concesiones de opciones y acciones restringidas, apoyando la contratación y retención de talento. Aunque la registración en sí no genera capital, cualquier emisión posterior de acciones diluirá progresivamente a los accionistas existentes.

2025ë…� 8ì›� 6ì�, Rigel Pharmaceuticals(RIGL)ëŠ� ì§ì› ì£¼ì‹ ë³´ìƒì� 위해 추가ë¡� 825,000ì£¼ì˜ ë³´í†µì£¼ë¥¼ 등ë¡í•˜ëŠ” 정기 Form S-8ì� 제출했습니다: ìœ ë„ ê³„íš í•˜ì— 125,000ì£�, 2018ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ ê³„íš í•˜ì— 700,000주입니다. ì´ë²ˆ ì œì¶œì€ ì´ì „ì� S-8 문서ë¥� 참조ë¡� í¬í•¨í•˜ë©°, ì¼ë°˜ì ì¸ 법률 ì˜ê²¬ì„�, ë™ì˜ì„� ë°� 위임ìž� ë¶€ì†ì„œë¥˜ë¥¼ í¬í•¨í•˜ê³  있습니다. 새로ìš� 수ìµ, 재무ìƒíƒœí‘� ë°ì´í„°ë‚˜ ì£¼ì‹ ë“±ë¡ ì™¸ì˜ ê¸°ì—… 활ë™ì€ í¬í•¨ë˜ì–´ 있지 않습니다. ì� ì„±ëª…ì€ Rigelì� 향후 ì£¼ì‹ ì˜µì…˜ ë°� 제한 ì£¼ì‹ ë¶€ì—¬ë¥¼ 위한 ì¶©ë¶„í•� 주ì‹ì� 보유하고 있ìŒì� 보장하며, ì¸ìž¬ 유치 ë°� 유지ì—� 기여합니ë‹�. ë“±ë¡ ìžì²´ëŠ� ìžë³¸ì� 조달하지 않지ë§�, ì´í›„ ì£¼ì‹ ë°œí–‰ì€ ê¸°ì¡´ ì£¼ì£¼ë“¤ì˜ ì§€ë¶� í¬ì„ì� ì ì§„ì ìœ¼ë¡� 초래í•� 것입니다.

Le 6 août 2025, Rigel Pharmaceuticals (RIGL) a déposé un formulaire S-8 de routine pour enregistrer 825 000 actions ordinaires supplémentaires destinées à la rémunération en actions des employés : 125 000 actions dans le cadre du Plan d'Induction et 700 000 actions dans le cadre du Plan d'Incitation en Actions 2018. Le dépôt intègre par référence les précédents formulaires S-8 et inclut les avis juridiques habituels, consentements et procurations annexes ; il ne contient aucune nouvelle donnée sur les résultats, le bilan ou des actions corporatives au-delà de l'enregistrement des actions. Cette déclaration garantit que Rigel dispose d'actions suffisantes pour les futures attributions d'options et d'actions restreintes, soutenant ainsi le recrutement et la fidélisation des talents. Bien que l'enregistrement lui-même ne génère pas de capital, toute émission ultérieure des actions diluera progressivement les actionnaires existants.

Am 6. August 2025 reichte Rigel Pharmaceuticals (RIGL) ein routinemäßiges Formular S-8 ein, um 825.000 zusätzliche Stammaktien für die Mitarbeiterbeteiligung zu registrieren: 125.000 Aktien im Rahmen des Inducement-Plans und 700.000 Aktien im Rahmen des Equity Incentive Plans 2018. Die Einreichung bezieht sich auf frühere S-8-Formulare und enthält die üblichen Rechtsgutachten, Zustimmungen und Vollmachtsanhänge; sie enthält keine neuen Gewinn-, Bilanzdaten oder Unternehmensmaßnahmen über die Aktienregistrierung hinaus. Die Erklärung stellt sicher, dass Rigel ausreichend Aktien für zukünftige Optionen und Restricted-Stock-Zuteilungen zur Verfügung hat, um die Rekrutierung und Bindung von Talenten zu unterstützen. Obwohl die Registrierung selbst kein Kapital einbringt, wird jede spätere Ausgabe der Aktien die bestehenden Aktionäre schrittweise verwässern.

 

As filed with the Securities and Exchange Commission on August 6, 2025

 

Registration No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 94-3248524
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

 

611 Gateway Boulevard, Suite 900

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

 

Rigel Pharmaceuticals, Inc. Inducement Plan, as Amended

Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as Amended

(Full title of the plan)

 

Raul R. Rodriguez

President and Chief Executive Officer

Rigel Pharmaceuticals, Inc.

611 Gateway Boulevard, Suite 900

South San Francisco, California 94080

(650) 624-1100 

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Carlton Fleming

Helen Theung

Sidley Austin LLP

555 California Street, Suite 2000

San Francisco, California 94104

(415) 772-1207

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer x
       
Non-accelerated filer ¨ Smaller reporting company ¨
       
    Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering: (i) an additional 125,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company” or the “Registrant”), to be issued pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended (the “Inducement Plan”), which shares of Common Stock are in addition to the shares of Common Stock registered on the Registrant’s Form S-8s filed with the Securities and Exchange Commission (the “Commission”) on  August 6, 2024 (File No. 333-281306), August 1, 2023 (File No. 333-273575), March 7, 2023 (File No. 333-270329)August 3, 2022 (File No. 333-266501)March 1, 2022 (File No. 333-263187)August 8, 2018 (File No. 333-226700)November 7, 2017 (File No. 333-221400)March 7, 2017 (File No. 333-216516), and November 1, 2016 (File No. 333-214370) and (ii) an additional 700,000 shares of Common Stock to be issued pursuant to the Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan,” and the Inducement Plan and the 2018 Plan, together, the “Plans”), which shares of Common Stock are in addition to the shares of Common Stock registered on the Registrant’s Form S-8s filed with the Commission on August 6, 2024 (File No. 333-281306), August 1, 2023 (File No. 333-273575), August 3, 2022 (File No. 333-266501)June 21, 2021 (File No. 333-257226)August 4, 2020 (File No. 333-240371)August 7, 2019 (File No. 333-233064), and August 8, 2018 (File No. 333-226700). The Registrant’s prior Form S-8s which are referenced in the preceding sentence are collectively referred to as the “Prior Form S-8s.”

 

This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Form S-8s relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8s, to the extent relating to the registration of Common Stock issuable under the applicable Plan, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as amended hereby.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3.         Incorporation of Documents by Reference.

 

The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

 

  · The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 4, 2025;
     
  · The Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025;
     
  · The Registrant’s Current Reports on Form 8-K, filed with the Commission on January 13, 2025, March 10, 2025, March 27, 2025 and May 23, 2025; and
     
  · The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on October 3, 2000, including any amendments or reports filed for the purpose of updating such description.

 

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

 

 

 

 

For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 8.         Exhibits.

 

Exhibit
Number
   
4.1(1)   Amended and Restated Certificate of Incorporation of the Registrant.
4.2(2)   Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.
4.3(3)   Certificate of Amendment of Certificate of Incorporation of the Registrant.
4.4(4)   Amended and Restated Bylaws of the Company.
4.5(5)   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant
4.6(6)   Specimen Common Stock Certificate of the Registrant.
5.1*   Opinion of Sidley Austin LLP.
23.1*   Consent of Independent Registered Public Accounting Firm.
23.2*   Consent of Sidley Austin LLP is contained in Exhibit 5.1 to this Registration Statement.
24.1*   Power of Attorney is contained on the signature pages to this Registration Statement.
99.1(7)   Rigel Pharmaceuticals, Inc. Inducement Plan, as amended.
99.2(7)   Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended.
107*   Calculation of Filing Fee Table.

 

(1) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on June 24, 2003.
   
(2) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on May 29, 2012.
   
(3) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on May 18, 2018.
   
(4) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on November 3, 2022.
   
(5) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on June 27, 2024.

 

(6) Document incorporated by reference to the Registrant’s Current Report on Form 8-K (No. 000-29889), filed with the Commission on June 24, 2003.
   
(7) Document incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q (No. 000-29889), filed with the Commission on August 5, 2025.
   
* Filed herewith.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on August 6, 2025.

 

  RIGEL PHARMACEUTICALS, INC.
     
  By: /s/ Raul Rodriguez
    Raul R. Rodriguez
    Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Raul R. Rodriguez and Dean Schorno, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the registrant to comply with the provisions of the Securities Act and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Raul R. Rodriguez   President, Chief Executive Officer and Director   August 6, 2025
Raul R. Rodriguez   (Principal Executive Officer)    
         
/s/ Dean Schorno   Chief Financial Officer   August 6, 2025
Dean Schorno   (Principal Financial and Accounting Officer)    
         
/s/ Gregg A. Lapointe        
Gregg A. Lapointe   Chairman of the Board of Directors   August 6, 2025
         
/s/ Kamil Ali-Jackson        
Kamil Ali-Jackson   Director   August 6, 2025
         
/s/ Mark W. Frohlich        
Mark W. Frohlich   Director   August 6, 2025
         
/s/ Alison L. Hannah        
Alison L. Hannah   Director   August 6, 2025
         
/s/ Walter H. Moos        
Walter H. Moos   Director   August 6, 2025
         
/s/ Jane Wasman        
Jane Wasman   Director   August 6, 2025

 

 

 

FAQ

How many additional RIGL shares are being registered in the August 6, 2025 Form S-8?

825,000 shares in total�125,000 for the Inducement Plan and 700,000 for the 2018 Equity Incentive Plan.

Does the S-8 filing raise new capital for Rigel Pharmaceuticals?

No. A Form S-8 only registers shares for employee benefit plans; it does not generate immediate cash proceeds.

Will existing Rigel shareholders be diluted by this registration?

Dilution occurs only when the registered shares are issued upon option exercise or award vesting.

Which equity plans are covered by Rigel’s latest S-8?

The Inducement Plan and the 2018 Equity Incentive Plan, both amended to add the new shares.

Why does Rigel use an Inducement Plan separate from its main incentive plan?

NASDAQ rules allow inducement grants to new hires outside shareholder-approved plans, aiding recruitment without waiting for annual meetings.
Rigel Pharmaceuticals Inc

NASDAQ:RIGL

RIGL Rankings

RIGL Latest News

RIGL Latest SEC Filings

RIGL Stock Data

730.77M
17.46M
2.65%
78.36%
14%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO